In people, there are reports of diabetic and non‐diabetic patients experiencing alterations in blood glucose levels, including hyperglycaemia and hypoglycaemia, with various receptor tyrosine kinase inhibitors (RTKIs), including sunitinib.51, 52, 53. This evidence concerns the gene NTRK1 and Hypoglycemia.